Shopping Cart
- Remove All
- Your shopping cart is currently empty
BAY 60-6583 is a potent, high-affinity adenosine A2B receptor agonist (EC50 = 3 nM) with affinity for A2B receptors that exceeds that for A1, A2A, and A3 receptors.BAY 60-6583 is cardioprotective in a model of myocardial ischemia.The Ki values for BAY 60-6583 binding to mouse, rabbit, and dog A2BAR were 750 nM, 340 nM, and 330 nM, respectively. The Ki values of BAY 60-6583 binding to A2BAR in mice, rabbits and dogs were 750 nM, 340 nM and 330 nM respectively.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $41 | In Stock | |
5 mg | $98 | In Stock | |
10 mg | $125 | In Stock | |
25 mg | $258 | In Stock | |
50 mg | $490 | In Stock | |
100 mg | $742 | In Stock | |
500 mg | $1,550 | In Stock | |
1 mL x 10 mM (in DMSO) | $108 | In Stock |
Description | BAY 60-6583 is a potent, high-affinity adenosine A2B receptor agonist (EC50 = 3 nM) with affinity for A2B receptors that exceeds that for A1, A2A, and A3 receptors.BAY 60-6583 is cardioprotective in a model of myocardial ischemia.The Ki values for BAY 60-6583 binding to mouse, rabbit, and dog A2BAR were 750 nM, 340 nM, and 330 nM, respectively. The Ki values of BAY 60-6583 binding to A2BAR in mice, rabbits and dogs were 750 nM, 340 nM and 330 nM respectively. |
Targets&IC50 | A2BAR (mouse):750 nM, A2BAR (rabbit):340 nM, A2B:3 nM(EC50), A2BAR (dog):330 nM |
In vitro | BAY 60-6583(0-10 μM) exhibits the maximum agonist effect of BAY 60-6583 in the absence of siRNA is 68 %.[3] BAY 60-6583 (5 μM; 24 h) induces a rise in cell accumulation within the G1 phase while concurrently reducing the G2/M phase in RAW264.7 preosteoclasts. Additionally, under the same conditions, BAY 60-6583 specifically impedes Akt activation triggered by M-CSF, with no discernible impact on M-CSF-induced ERK1/2 activation in RAW264.7 preosteoclasts.[4] |
In vivo | BAY 60-6583 (100 mg/kg; intravenous injection; rabbit) administered just before reperfusion, diminishes the infarction area in ischemic rabbit hearts.[1] BAY 60-6583 (2 mg/kg; intravenous injection; mice) attenuates LPS-induced lung injury, pre-treatment with this compound can significantly decrease LPS-increased, IL-6 levels in WT mice.[2] |
Molecular Weight | 379.44 |
Formula | C19H17N5O2S |
Cas No. | 910487-58-0 |
Smiles | NC(=O)CSc1nc(N)c(C#N)c(-c2ccc(OCC3CC3)cc2)c1C#N |
Relative Density. | 1.43 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 90.0 mg/mL (237.2 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.